Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

313.25 +4.78 (+1.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
23 24 Next >
Can Biotech Stocks Continue Rallying In This Bear Market?
Via Talk Markets
Here's a No-Brainer Stock to Buy Now That's Trouncing the Market
There are five great reasons this stock should continue to soar. 
Via The Motley Fool
The Best Stocks to Invest $20,000 in Right Now
A long-term investment in any of these powerhouse stocks could reap generous returns for many years to come. 
Via The Motley Fool
5 Top Stocks for November
A dynamic blend of growth, value, and dividend stocks worth considering now. 
Via The Motley Fool
This Bear Market Could Be the Best Investing Opportunity in More Than a Decade
It could be time to party like it's 2009. 
Via The Motley Fool
Why Shares of Vertex Pharmaceuticals Jumped 9.03% on Friday
A strong earnings report after the close on Thursday pushed the stock higher all day Friday. 
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q3 2022 Earnings Call Transcript
VRTX earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Vertex Pharmaceuticals Jumps After Quarterly Beat, Raises 2022 Outlook
Shares tumbled 7.5% during the regular session, ahead of the quarterly beat. 
Via Investor's Business Daily
Expert Ratings for Vertex Pharmaceuticals
Vertex Pharmaceuticals (NASDAQ:VRTX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Stock Market Rally Resilient As Apple Bucks Megacap Meltdown: Weekly Review
The Dow and S&P 500 moved above a key level while the Nasdaq rose. 
Via Investor's Business Daily
Cramer Says Stay With This Stock As It Is 'Really, Really Well-Run Company'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended staying with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), and added that it’s a "really, really well-run company." 
Via Benzinga
Vertex Reports Third Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Unusual Options Activity For October 27
A whale with a lot of money to spend has taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 13 strange trades. 
Via Benzinga
US Stocks On Track For Mixed Start As Nasdaq Futures Sag Yet Again Amid Big Tech Woes; Traders Look Ahead To Q3 GDP Data, Apple, Amazon Earnings
Trading in the U.S. index futures points to a mixed opening by Wall Street stocks on Thursday, as tech earnings continue to disappoint. 
Via Benzinga
2 Monster Stocks to Buy Without Any Hesitation
These stocks are crushing the bear market. 
Via The Motley Fool
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Vertex Pharmaceuticals's (NASDAQ:VRTX) short percent of float has risen 7.08% since its last report. The company recently reported that it has 3.11 million shares sold short, which is 1.21% of all... 
Via Benzinga
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
Analyst Ratings for Vertex Pharmaceuticals
Over the past 3 months, 5 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Which Stocks Are Most Likely to Thrive in a Recession? Here's What History Shows
Recession-proof stocks must offer something that makes investors want to buy them even when the economy is tanking. 
Via The Motley Fool
2 Powerhouse Stocks That Could Go Parabolic
These stocks could take you by surprise. 
Via The Motley Fool
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
Procrastination could be problematic with these three bargain stocks. 
Via The Motley Fool
S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength
Vertex and LNG play Cheniere Energy are setting up bullishly. 
Via Investor's Business Daily
The Top 5 Stocks Cathie Wood Bought and Sold This Week
Cathie Wood's flagship ETF, the ARK Innovation ETF, hit a five-year and 52-week low this week, casting doubts on the investment manager. 
Via InvestorPlace
These 3 Stocks Are Winning the Bear Market -- Here's How
Picking the right markets to compete in makes surviving bear markets much more manageable for these companies. 
Via The Motley Fool
This Beaten-Down ETF Is Still a Screaming Bear-Market Buy
Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund. 
Via The Motley Fool
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
2 Unstoppable Stocks That Are Beating the Bear Market
Is it too late to buy these stocks or are their shares likely to continue rising? 
Via The Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
These biotech companies have a long ramp of revenue growth ahead. 
Via The Motley Fool
If You Invested $100 In This Stock 15 Years Ago, You Would Have $900 Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 9.87% on an annualized basis producing an average annual return of 15.93%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
23 24 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.